M Miles Braun

Thromboembolic adverse events after use of recombinant human coagulation factor VIIa.

M. Braun, J. Lozier, J. J. Wood, 2006, JAMA.

Potential population‐based electronic data sources for rapid pandemic influenza vaccine adverse event detection: a survey of health plans

Richard Platt, R. Platt, Jeffrey S. Brown, 2008, Pharmacoepidemiology and drug safety.

Adverse events reported following live, cold-adapted, intranasal influenza vaccine.

Robert Ball, Douglas Pratt, John Iskander, 2005, JAMA.

Development of case definitions for acute encephalopathy, encephalitis, and multiple sclerosis reports to the vaccine: Adverse Event Reporting System.

Robert Ball, Lawrence H Moulton, Neal Halsey, 2002, Journal of clinical epidemiology.

Adverse event reports following yellow fever vaccination.

A. Hinckley, M. Braun, J. E. Staples, 2008, Vaccine.

Effects of Stratification on Data Mining in the US Vaccine Adverse Event Reporting System (VAERS)

Robert Ball, Emily Jane Woo, D. Burwen, 2008, Drug safety.

Autologous cultured chondrocytes: adverse events reported to the United States Food and Drug Administration.

Eda T Bloom, F. Frassica, M. Braun, 2006, The Journal of bone and joint surgery. American volume.

Active Influenza Vaccine Safety Surveillance: Potential Within a Healthcare Claims Environment

Richard Platt, Martin Kulldorff, M. Kulldorff, 2009, Medical care.

Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine.

Robert Ball, Emily Jane Woo, John Iskander, 2009, JAMA.